Younas, Neelam

[["dc.bibliographiccitation.firstpage","e1006797"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","PLoS Pathogens"],["dc.bibliographiccitation.volume","14"],["dc.contributor.author","Sevillano, Alejandro M."],["dc.contributor.author","Fernández-Borges, Natalia"],["dc.contributor.author","Younas, Neelam"],["dc.contributor.author","Wang, Fei"],["dc.contributor.author","R. Elezgarai, Saioa"],["dc.contributor.author","Bravo, Susana"],["dc.contributor.author","Vázquez-Fernández, Ester"],["dc.contributor.author","Rosa, Isaac"],["dc.contributor.author","Eraña, Hasier"],["dc.contributor.author","Gil, David"],["dc.contributor.author","Veiga, Sonia"],["dc.contributor.author","Vidal, Enric"],["dc.contributor.author","Erickson-Beltran, Melissa L."],["dc.contributor.author","Guitián, Esteban"],["dc.contributor.author","Silva, Christopher J."],["dc.contributor.author","Nonno, Romolo"],["dc.contributor.author","Ma, Jiyan"],["dc.contributor.author","Castilla, Joaquín"],["dc.contributor.author","R. Requena, Jesús"],["dc.contributor.editor","Supattapone, Surachai"],["dc.date.accessioned","2020-12-10T18:42:11Z"],["dc.date.available","2020-12-10T18:42:11Z"],["dc.date.issued","2018"],["dc.identifier.doi","10.1371/journal.ppat.1006797"],["dc.identifier.eissn","1553-7374"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/77839"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Recombinant PrPSc shares structural features with brain-derived PrPSc: Insights from limited proteolysis"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","S0167488922000313"],["dc.bibliographiccitation.firstpage","119240"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","Biochimica et Biophysica Acta (BBA) - Molecular Cell Research"],["dc.bibliographiccitation.volume","1869"],["dc.contributor.author","Shafiq, Mohsin"],["dc.contributor.author","Da Vela, Stefano"],["dc.contributor.author","Amin, Ladan"],["dc.contributor.author","Younas, Neelam"],["dc.contributor.author","Harris, David A."],["dc.contributor.author","Zerr, Inga"],["dc.contributor.author","Altmeppen, Hermann C."],["dc.contributor.author","Svergun, Dmitri"],["dc.contributor.author","Glatzel, Markus"],["dc.date.accessioned","2022-04-01T10:02:21Z"],["dc.date.available","2022-04-01T10:02:21Z"],["dc.date.issued","2022"],["dc.identifier.doi","10.1016/j.bbamcr.2022.119240"],["dc.identifier.pii","S0167488922000313"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/105883"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-530"],["dc.relation.issn","0167-4889"],["dc.rights.uri","https://www.elsevier.com/tdm/userlicense/1.0/"],["dc.title","The prion protein and its ligands: Insights into structure-function relationships"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","265"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Journal of Alzheimer's Disease"],["dc.bibliographiccitation.lastpage","275"],["dc.bibliographiccitation.volume","59"],["dc.contributor.author","Zafar, Saima"],["dc.contributor.author","Shafiq, Mohsin"],["dc.contributor.author","Younas, Neelam"],["dc.contributor.author","Schmitz, Matthias"],["dc.contributor.author","Ferrer, Isidre"],["dc.contributor.author","Zerr, Inga"],["dc.date.accessioned","2020-12-10T18:44:11Z"],["dc.date.available","2020-12-10T18:44:11Z"],["dc.date.issued","2017"],["dc.identifier.doi","10.3233/JAD-170237"],["dc.identifier.eissn","1875-8908"],["dc.identifier.issn","1387-2877"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/78355"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Prion Protein Interactome: Identifying Novel Targets in Slowly and Rapidly Progressive Forms of Alzheimer’s Disease"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Molecular Neurobiology"],["dc.contributor.author","Zafar, Saima"],["dc.contributor.author","Younas, Neelam"],["dc.contributor.author","Sheikh, Nadeem"],["dc.contributor.author","Tahir, Waqas"],["dc.contributor.author","Shafiq, Mohsin"],["dc.contributor.author","Schmitz, Matthias"],["dc.contributor.author","Ferrer, Isidre"],["dc.contributor.author","Andréoletti, Olivier"],["dc.contributor.author","Zerr, Inga"],["dc.date.accessioned","2020-12-10T14:14:25Z"],["dc.date.available","2020-12-10T14:14:25Z"],["dc.date.issued","2017"],["dc.identifier.doi","10.1007/s12035-017-0589-0"],["dc.identifier.eissn","1559-1182"],["dc.identifier.issn","0893-7648"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/71344"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Cytoskeleton-Associated Risk Modifiers Involved in Early and Rapid Progression of Sporadic Creutzfeldt-Jakob Disease"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","14166"],["dc.bibliographiccitation.issue","22"],["dc.bibliographiccitation.journal","International Journal of Molecular Sciences"],["dc.bibliographiccitation.volume","23"],["dc.contributor.author","Zafar, Saima"],["dc.contributor.author","Noor, Aneeqa"],["dc.contributor.author","Younas, Neelam"],["dc.contributor.author","Shafiq, Mohsin"],["dc.contributor.author","Schmitz, Matthias"],["dc.contributor.author","Wurster, Isabel"],["dc.contributor.author","Brockmann, Kathrin"],["dc.contributor.author","Gasser, Thomas"],["dc.contributor.author","Zerr, Inga"],["dc.date.accessioned","2022-12-01T08:31:42Z"],["dc.date.available","2022-12-01T08:31:42Z"],["dc.date.issued","2022"],["dc.description.abstract","β-glucocerebrosidase (GBA)-associated mutations are a significant risk factor for Parkinson’s disease (PD) that aggravate the disease pathology by upregulating the deposition of α-Synuclein (α-Syn). The resultant clinical profile varies for PD patients without GBA mutations. The current study aimed to identify the proteomic targets involved in the pathogenic pathways leading to the differential clinical presentation of GBA-associated PD. CSF samples (n = 32) were obtained from PD patients with GBA mutations (n = 22), PD patients without GBA mutations (n = 7), and healthy controls that were carriers of GBA mutations (n = 3). All samples were subjected to in-gel tryptic digestion followed by the construction of the spectral library and quantitative SWATH-based analysis. CSF α-Syn levels were reduced in both PDIdiopathic and PDGBA cases. Our SWATH-based mass spectrometric analysis detected 363 proteins involved in immune response, stress response, and cell signaling in various groups. Intergroup analysis showed that 52 proteins were significantly up- or downregulated in various groups. Of these 52 targets, 20 proteins were significantly altered in PDGBA cases only while 2 showed different levels in PDIdiopathic patients. Our results show that the levels of several pathologically relevant proteins, including Contactin-1, Selenium-binding protein 1, Adhesion G Protein-Coupled Receptor, and Apolipoprotein E are significantly different among the sporadic and genetic variants of PD and hint at aggravated synaptic damage, oxidative stress, neuronal loss, and aggregation of α-Syn in PDGBA cases."],["dc.identifier.doi","10.3390/ijms232214166"],["dc.identifier.pii","ijms232214166"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/118243"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-621"],["dc.relation.eissn","1422-0067"],["dc.title","SWATH Mass Spectrometry-Based CSF Proteome Profile of GBA-Linked Parkinson’s Disease Patients"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Molecular Neurobiology"],["dc.contributor.author","Noor, Aneeqa"],["dc.contributor.author","Zafar, Saima"],["dc.contributor.author","Shafiq, Mohsin"],["dc.contributor.author","Younas, Neelam"],["dc.contributor.author","Siegert, Anna"],["dc.contributor.author","Mann, Florian A."],["dc.contributor.author","Kruss, Sebastian"],["dc.contributor.author","Schmitz, Matthias"],["dc.contributor.author","Dihazi, Hassan"],["dc.contributor.author","Ferrer, Isidre"],["dc.contributor.author","Zerr, Inga"],["dc.date.accessioned","2021-12-01T09:23:29Z"],["dc.date.available","2021-12-01T09:23:29Z"],["dc.date.issued","2021"],["dc.description.abstract","Abstract The molecular determinants of atypical clinical variants of Alzheimer’s disease, including the recently discovered rapidly progressive Alzheimer’s disease (rpAD), are unknown to date. Fibrilization of the amyloid-β (Aβ) peptide is the most frequently studied candidate in this context. The Aβ peptide can exist as multiple proteoforms that vary in their post-translational processing, amyloidogenesis, and toxicity. The current study was designed to identify these variations in Alzheimer’s disease patients exhibiting classical (sAD) and rapid progression, with the primary aim of establishing if these variants may constitute strains that underlie the phenotypic variability of Alzheimer’s disease. We employed two-dimensional polyacrylamide gel electrophoresis and MALDI-ToF mass spectrometry to validate and identify the Aβ proteoforms extracted from targeted brain tissues. The biophysical analysis was conducted using RT-QuIC assay, confocal microscopy, and atomic force microscopy. Interactome analysis was performed by co-immunoprecipitation. We present a signature of 33 distinct pathophysiological proteoforms, including the commonly targeted Aβ 40 , Aβ 42 , Aβ 4-42 , Aβ 11-42 , and provide insight into their synthesis and quantities. Furthermore, we have validated the presence of highly hydrophobic Aβ seeds in rpAD brains that seeded reactions at a slower pace in comparison to typical Alzheimer’s disease. In vitro and in vivo analyses also verified variations in the molecular pathways modulated by brain-derived Aβ. These variations in the presence, synthesis, folding, and interactions of Aβ among sAD and rpAD brains constitute important points of intervention. Further validation of reported targets and mechanisms will aid in the diagnosis of and therapy for Alzheimer’s disease."],["dc.description.abstract","Abstract The molecular determinants of atypical clinical variants of Alzheimer’s disease, including the recently discovered rapidly progressive Alzheimer’s disease (rpAD), are unknown to date. Fibrilization of the amyloid-β (Aβ) peptide is the most frequently studied candidate in this context. The Aβ peptide can exist as multiple proteoforms that vary in their post-translational processing, amyloidogenesis, and toxicity. The current study was designed to identify these variations in Alzheimer’s disease patients exhibiting classical (sAD) and rapid progression, with the primary aim of establishing if these variants may constitute strains that underlie the phenotypic variability of Alzheimer’s disease. We employed two-dimensional polyacrylamide gel electrophoresis and MALDI-ToF mass spectrometry to validate and identify the Aβ proteoforms extracted from targeted brain tissues. The biophysical analysis was conducted using RT-QuIC assay, confocal microscopy, and atomic force microscopy. Interactome analysis was performed by co-immunoprecipitation. We present a signature of 33 distinct pathophysiological proteoforms, including the commonly targeted Aβ 40 , Aβ 42 , Aβ 4-42 , Aβ 11-42 , and provide insight into their synthesis and quantities. Furthermore, we have validated the presence of highly hydrophobic Aβ seeds in rpAD brains that seeded reactions at a slower pace in comparison to typical Alzheimer’s disease. In vitro and in vivo analyses also verified variations in the molecular pathways modulated by brain-derived Aβ. These variations in the presence, synthesis, folding, and interactions of Aβ among sAD and rpAD brains constitute important points of intervention. Further validation of reported targets and mechanisms will aid in the diagnosis of and therapy for Alzheimer’s disease."],["dc.identifier.doi","10.1007/s12035-021-02566-9"],["dc.identifier.pii","2566"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/94665"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-478"],["dc.relation.eissn","1559-1182"],["dc.relation.issn","0893-7648"],["dc.title","Molecular Profiles of Amyloid-β Proteoforms in Typical and Rapidly Progressive Alzheimer’s Disease"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Prion"],["dc.bibliographiccitation.volume","9"],["dc.contributor.author","Sevillano, Alejandro M."],["dc.contributor.author","Fernandez-Borges, Natalia"],["dc.contributor.author","Younas, Neelam"],["dc.contributor.author","Vazquez-Fernandez, Ester"],["dc.contributor.author","Elezgarai, Saioa R."],["dc.contributor.author","Erana, Hasier"],["dc.contributor.author","Nonno, Romolo"],["dc.contributor.author","Castilla, Joaquin"],["dc.contributor.author","Requena, Jesus R."],["dc.date.accessioned","2018-11-07T09:58:22Z"],["dc.date.available","2018-11-07T09:58:22Z"],["dc.date.issued","2015"],["dc.format.extent","S8"],["dc.identifier.isi","000354444900015"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/37348"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Taylor & Francis Inc"],["dc.publisher.place","Philadelphia"],["dc.relation.issn","1933-690X"],["dc.relation.issn","1933-6896"],["dc.title","The architecture of recombinant prions is similar to that of brain-derived prions: Insights from limited proteolysis"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","697"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Molecular Neurobiology"],["dc.bibliographiccitation.lastpage","709"],["dc.bibliographiccitation.volume","54"],["dc.contributor.author","Zafar, Saima"],["dc.contributor.author","Younas, Neelam"],["dc.contributor.author","Correia, Susana"],["dc.contributor.author","Shafiq, Mohsin"],["dc.contributor.author","Tahir, Waqas"],["dc.contributor.author","Schmitz, Matthias"],["dc.contributor.author","Ferrer, Isidre"],["dc.contributor.author","Andreoletti, Olivier"],["dc.contributor.author","Zerr, Inga"],["dc.date.accessioned","2018-11-07T10:29:22Z"],["dc.date.available","2018-11-07T10:29:22Z"],["dc.date.issued","2017"],["dc.description.abstract","There is an increasing demand for the understanding of pathophysiology on neurodegeneration diseases at early stages. Changes in endocytic machinery and the cytoskeleton-associated response are the first alterations observed in Creutzfeldt-Jakob disease (CJD) and Alzheimer's disease AD brain. In this study, we performed a targeted search for endocytic pathway proteins in the different regions of the brain. We found late endosome marker Rab7a which was significantly upregulated in the frontal cortex region in the rapid progressive CJD form (MM1) and rapid progressive AD (rpAD) forms. However, Rab9 expression was significantly downregulated only in CJD-MM1 brain frontal cortex region. In the cerebellum, Rab7a expression showed significant upregulation in both subtype MM1 and VV2 CJD forms, in contrast to Rab9 which showed significant downregulation in both subtype MM1 and VV2 CJD forms at terminal stage of the disease. To check regulatory response at pre-symptomatic stage of the disease, we checked the regulatory interactive response of Rab7a, Rab9, and known biomarkers PrPC and tau forms in frontal cortex at pre-symptomatic stage of the disease in tg340 mice expressing about fourfold of human PrP-M129 with PrP-null background that had been inoculated with human sCJD MM1 brain tissue homogenates (sCJD MM1 mice). In addition, we analyzed 5XFAD mice, exhibiting five mutations in the APP and presenilin genes related to familial Alzheimer's disease (FAD), to validate specific regulatory response of Rab7a, Rab9, tau, and phosphorylated form of tau by immunostaining 5XFAD mice in comparison with the wild-type age-matched mice brain. The cortical region of 5XFAD mice brain showed accumulated form of Rab7a in puncta that co-label for p-Tau, indicating colocalization by using confocal laser-scanning microscopy and was confirmed by using reverse co-immunoprecipitation. Furthermore, synthetic RNA (siRNA) against the Rab7a gene decreased expression of Rab7a protein, in cortical primary neuronal cultures of PrPC wild type. This depleted expression of Rab7a led to the increased accumulation of PrPC in Rab9-positive endosomal compartments and consequently an increased co-localization between PrPC/Rab9; however, total tau level decreased. Interestingly, siRNA against tau gene in cortical primary neuronal cultures of PrPC wild-type mice showed enhanced Rab7a and Rab9 expression and increase formation of dendritic spines. The work described highlighted the selective involvement of late endosomal compartment marker Rab7a in CJD, slow and rapid progressive forms of AD pathogenesis."],["dc.identifier.doi","10.1007/s12035-016-9694-8"],["dc.identifier.isi","000392133900058"],["dc.identifier.pmid","26768426"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/43631"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","PUB_WoS_Import"],["dc.publisher","Humana Press Inc"],["dc.relation.issn","1559-1182"],["dc.relation.issn","0893-7648"],["dc.title","Strain-Specific Altered Regulatory Response of Rab7a and Tau in Creutzfeldt-Jakob Disease and Alzheimer's Disease"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Prion"],["dc.bibliographiccitation.volume","10"],["dc.contributor.author","Shafiq, Mohsin"],["dc.contributor.author","Zafar, Saima"],["dc.contributor.author","Younas, Neelam"],["dc.contributor.author","Schmitz, Matthias"],["dc.contributor.author","Ferrer, Isidre"],["dc.contributor.author","Zerr, Inga"],["dc.date.accessioned","2018-11-07T10:20:26Z"],["dc.date.available","2018-11-07T10:20:26Z"],["dc.date.issued","2016"],["dc.format.extent","S97"],["dc.identifier.isi","000374656300138"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/41892"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Taylor & Francis Inc"],["dc.publisher.place","Philadelphia"],["dc.relation.issn","1933-690X"],["dc.relation.issn","1933-6896"],["dc.title","Prion protein interactome: Identifying novel targets in rapidly progressive Alzheimer's disease"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","S102"],["dc.bibliographiccitation.journal","Prion"],["dc.bibliographiccitation.lastpage","S103"],["dc.bibliographiccitation.volume","10"],["dc.contributor.author","Younas, Neelam"],["dc.contributor.author","Zafar, Saima"],["dc.contributor.author","Shafiq, Mohsin"],["dc.contributor.author","Tahir, Waqas"],["dc.contributor.author","Schmitz, Mathias"],["dc.contributor.author","Ferrer, Isidre"],["dc.contributor.author","Andreoletti, Olivier"],["dc.contributor.author","Zerr, Inga"],["dc.date.accessioned","2018-11-07T10:20:26Z"],["dc.date.available","2018-11-07T10:20:26Z"],["dc.date.issued","2016"],["dc.identifier.isi","000374656300145"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/41893"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Taylor & Francis Inc"],["dc.publisher.place","Philadelphia"],["dc.relation.issn","1933-690X"],["dc.relation.issn","1933-6896"],["dc.title","Early response of Cofilin1 pathway in Creutzfeldt Jakob disease"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]